Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon has warned healthcare professionals against prescribing pain killer Fentora off-label after some patients treated with the drug died.
Subscribe to our email newsletter
Fentora is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
The US biopharmaceutical company said that the deaths from respiratory depression occurred as a result of prescribing the drug to opioid non-tolerant patients, improper dosing, and/or improper product substitution. Cephalon has written to healthcare professionals highlighting the issues and has alerted the FDA.
Fentora contains fentanyl, an opioid agonist, which has a high potential for abuse and overdose.